Prostate Cancer Outcomes: An International Registry to Improve Outcomes in Men With Advanced Prostate Cancer (IRONMAN)


Condition: Prostate Cancer

Intervention:

  • Other: Standard of Care

Purpose: Our intent is to establish the International Registry to Improve Outcomes in Men with Advanced Prostate Cancer (IRONMAN) as a prospective, international cohort of minimum 5,000 men with advanced cancer, including men with mHSPC and M0/M1 CRPC. The goal is to establish a population-based registry and recruit patients across academic and community practices from Australia, Brazil, Canada, Ireland, Sweden, Switzerland, the United Kingdom (UK), and the US. Target accrual number and number of participating sites are subject to change based on accrual, funding, and interest in participation by other international sites. This cohort study will facilitate a better understanding of the variation in care and treatment of advanced prostate cancer across countries and across academia and community based practices. Detailed data will be collected from patients at study enrollment and then during follow-up, for a minimum of three years. Patients will be followed prospectively for overall survival, clinically significant adverse events, comorbidities, changes in cancer treatments, and PROMs. PROMs questionnaires will be collected at enrollment, every three months for the first and second year then every six months. Physician Questionnaires will be collected from all participating sites at patient enrollment, time of first change in treatment and/or one year follow-up, at each subsequent change of treatment, and discontinuation of treatment. As such, this registry will help identify the treatment sequences or combinations that optimize overall survival and PROMs for men with mHSPC and M0/M1 CRPC. By collecting blood at enrollment, time of first change in treatment and/or one year follow-up (plasma, cell free DNA, buffy coat / RNA), this registry will further identify and validate molecular phenotypes of disease that predict response and resistance to specific therapeutics. Additionally, every effort will be made to collect blood specimen at each subsequent change in treatment. When feasible, existing tumor tissue may be collected for correlation with described blood based studies. All samples will be used for future research. This cohort study will provide the research community with a unique biorepository to identify biomarkers of treatment response and resistance.

Study Type: Observational [Patient Registry]

Clinical Trials Identifier NCT 8-digits: NCT03151629

Sponsor: Prostate Cancer Clinical Trials Consortium

Primary Outcome Measures:

  • Measure: Practice Patterns
  • Time Frame: 5 years
  • Safety Issue:

Estimated Enrollment: 5000

Study Start Date: May 1, 2017

Notice: Undefined property: stdClass::$phase in /home/urotoday/public_html/administrator/components/com_clinicaltrials/ClinicalTrials/Trial.php on line 192

Phase: Notice: Undefined property: stdClass::$phase in /home/urotoday/public_html/administrator/components/com_clinicaltrials/ClinicalTrials/Trial.php on line 192

Eligibility:

  • Age: minimum 18 Years maximum N/A
  • Gender: Male

Criteria: • Willing and able to provide written informed consent and privacy authorization for the release of personal health information. NOTE: Privacy authorization may be either included in the informed consent or obtained separately. - Males 21 years of age and above - Histological or cytological confirmed prostate adenocarcinoma from TRUS biopsy, radical prostatectomy or TURP Or Documented histopathology or cytopathology of prostate adenocarcinoma from a biopsy of a metastatic site Or Metastatic disease typical of prostate cancer (i.e., involving bone or pelvic lymph nodes or para-aortic lymph nodes) AND a serum concentration of PSA >20ng/mL - No previous diagnosis of a second, non-prostate malignancy that requires additional systemic therapy except cancer in situ of bladder and basal cell cancer of skin

Contact:

  • Jacob Vinson
  • 646-888-0421

Locations:

  • Robert H. Lurie Comprehensive Cancer Center of Northwestern University
  • Chicago Illinois 60611 United States
  • University of Chicago
  • Chicago Illinois 60637 United States
  • Tulane University
  • New Orleans Louisiana 70112 United States
  • Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
  • Baltimore Maryland 21231 United States
  • Dana-Farber Cancer Institute
  • Boston Massachusetts 02215 United States
  • University of Michigan
  • Ann Arbor Michigan 48109 United States
  • Karmanos Cancer Institute
  • Detroit Michigan 48201 United States
  • Memorial Sloan Kettering Cancer Center
  • New York New York 10065 United States
  • University of North Carolina at Chapel Hill
  • Chapel Hill North Carolina 27514 United States
  • Duke University
  • Durham North Carolina 27710 United States
  • Thomas Jefferson University
  • Philadelphia Pennsylvania 19107 United States
  • Baylor College of Medicine
  • Houston Texas 77030 United States
  • University of Virginia
  • Charlottesville Virginia 22903 United States

View trial on ClinicalTrials.gov


E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe